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This study evaluated the efﬁcacy and safety of lisdexamfetamine dimesylate (LDX) compared
with placebo in children and adolescents with attention-deﬁcit/hyperactivity disorder (ADHD)
in Europe. Osmotic-release oral system methylphenidate (OROS-MPH) was included as a
reference arm. Patients (6–17 years old) with a baseline ADHD Rating Scale version IV (ADHD-
RS-IV) total score Z28 were randomized (1:1:1) to dose-optimized LDX (30, 50, or 70 mg/day),
OROS-MPH (18, 36, or 54 mg/day) or placebo for 7 weeks. Primary and key secondary efﬁcacy
measures were the investigator-rated ADHD-RS-IV and the Clinical Global Impressions-
Improvement (CGI-I) rating, respectively. Safety assessments included treatment-emergent
adverse events (TEAEs), electrocardiograms, and vital signs. Of 336 patients randomized, 196
completed the study. The difference between LDX and placebo in least squares mean change in
ADHD-RS-IV total score from baseline to endpoint was 18.6 (95% conﬁdence interval [CI]:Elsevier B.V. and ECNP. All rights reserved.
o.2012.11.012
8 220 4004; fax: +44 138 234 6555.
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1209Study of LDX in children and adolescents with ADHD21.5 to 15.7) (po0.001; effect size, 1.80). The difference between OROS-MPH and placebo
in least squares mean change in ADHD-RS-IV total score from baseline to endpoint was 13.0
(95% CI: 15.9 to 10.2) (po0.001; effect size, 1.26). The proportions (95% CI) of patients
showing improvement (CGI-I of 1 or 2) at endpoint were 78% (70–86), 14% (8–21), and 61% (51–
70) for LDX, placebo, and OROS-MPH. The most common TEAEs for LDX were decreased
appetite, headache, and insomnia. Mean changes in vital signs were modest and consistent with
the known proﬁle of LDX. LDX was effective and generally well tolerated in children and
adolescents with ADHD.
& 2012 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is one of the
most common neurodevelopmental disorders diagnosed in
children, with an estimated worldwide prevalence of 5.29%
(Polanczyk et al., 2007). ADHD is characterized by persistent
core symptoms of hyperactivity, impulsivity, and/or inattention,
and is associated with impairments in academic, social, and
interpersonal functioning (American Academy of Pediatrics,
2011a; Gordon et al., 2006). Stimulant medications are com-
monly recommended as part of a comprehensive multimodal
treatment plan for ADHD that will often also include behavioral,
psychoeducational, and psychological interventions (American
Academy of Pediatrics, 2011b; Banaschewski et al., 2006;
National Institute for Health and Clinical Excellence, 2009;
Taylor et al., 2004). Stimulants are available in long-acting and
short-acting formulations. In addition to reducing or eliminating
the need for multiple daily dosing, the suggested beneﬁts of
long-acting stimulants also include improved adherence and
lower abuse potential compared with their short-acting coun-
terparts (Banaschewski et al., 2006).
Lisdexamfetamine dimesylate (LDX) is the ﬁrst long-
acting, prodrug stimulant. The intact parent molecule
requires enzymatic hydrolysis to yield the therapeutically-
active metabolite d-amfetamine (Pennick, 2010). After oral
administration, LDX is readily absorbed from the gastro-
intestinal tract. As the metabolic conversion of LDX to
d-amfetamine occurs primarily in the blood, it is unlikely
to be affected by changes in gastric pH or variations in
gastrointestinal transit time (Pennick, 2010). Pharmacoki-
netic studies in children with ADHD have shown that,
following oral administration of LDX, exposure to d-amfe-
tamine is long lasting and dose proportional, with low
intrapatient and interpatient variability (Biederman et al.,
2007a; Boellner et al., 2010).
All clinical trials of LDX reported to date have been
conducted in the United States. These studies have shown
LDX to be an effective once-daily treatment for ADHD in
children (Biederman et al., 2007b), adolescents (Findling
et al., 2011), and adults (Adler et al., 2008). Studies in a
laboratory school setting and in a simulated adult workplace
environment have demonstrated that the therapeutic
beneﬁts of LDX are ongoing at 13 h post-dose in children
(Wigal et al., 2009) and 14 h post-dose in adults (Wigal
et al., 2010). The present European, phase 3 trial evaluated
the efﬁcacy and safety of LDX over the course of 7 weeks in
children and adolescents (6–17 years old) diagnosed with
ADHD of at least moderate severity. Osmotic-release oral
system methylphenidate (OROS-MPH) was included as a
reference arm.2. Experimental procedures
This randomized, double-blind, parallel-group, dose-optimized,
placebo-controlled study (ClinicalTrials.gov Identiﬁer: NCT00763971)
was conducted in accordance with the current applicable regulations,
the International Conference on Harmonisation of Good Clinical
Practice, and local ethical and legal requirements. The study protocol
was approved by an independent ethics committee/institutional
review board and regulatory agency in each center (as appropriate)
before study initiation. Each patient’s parent or legal guardian
provided written, informed consent, and assent was obtained from
each participant, as applicable, before commencing study-related
procedures.
2.1. Study population
The study enrolled male and female children (6–12 years old) and
adolescents (13–17 years old) who satisﬁed the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revi-
sion (DSM-IV-TR) criteria for a primary diagnosis of ADHD (American
Psychiatric Association, 2000). Patients had ADHD of at least
moderate severity, as deﬁned by a baseline ADHD Rating Scale
version IV (ADHD-RS-IV) total score of 28 or higher. Additional
inclusion criteria included: age-appropriate intellectual function-
ing; blood pressure measurements within the 95th percentile for
age, sex, and height; and ability to swallow a capsule. Girls of
childbearing potential had to have a negative urine pregnancy test
at baseline and to comply with any contraceptive requirements of
the protocol.
Key exclusion criteria included: failure to respond to previous
OROS-MPH therapy; presence of a comorbid psychiatric diagnosis
with signiﬁcant symptoms (based on Kiddie-Schedule for Affective
Disorders and Schizophrenia for school age children – Present and
Lifetime – diagnostic interview); conduct disorder (excluding oppo-
sitional deﬁant disorder); pregnancy or lactation; weight below
22.7 kg; body mass index (BMI, kg/m2) greater than the 97th
percentile for age and sex; positive urine drug test (with the
exception of the patient’s current ADHD therapy); clinically sig-
niﬁcant electrocardiogram or laboratory abnormalities; suspected
substance abuse or dependence disorder (excluding nicotine) within
the previous 6 months; history of seizures; tics or Tourette’s
disorder; known structural cardiac abnormality; or any other
condition that might increase vulnerability to the sympathomimetic
effects of a stimulant drug. Patients whose current ADHD medica-
tion provided effective control of symptoms with acceptable
tolerability were also excluded.
2.2. Study drug administration
Eligible patients completed a screening and washout period (3–42
days) and were randomized in a 1:1:1 ratio at baseline (visit 0) to
receive once-daily LDX, OROS-MPH, or placebo for a 7-week double-
blind evaluation period (4-week stepwise dose-optimization period
D. Coghill et al.1210[visits 1–4] and 3-week dose-maintenance period [visits 5–7]), fol-
lowed by an immediate 1-week washout and safety follow-up (visit 8).
LDX was administered as 30, 50, or 70 mg capsules and OROS-MPH as
18, 36, or 54 mg tablets (54 mg/day is the maximum approved dose of
OROS-MPH in Europe). An interactive voice/web response system was
used to allocate a unique randomization number to each patient.
Study drugs were over-encapsulated and appeared identical. Rando-
mization was stratiﬁed by country and age group (6–12 or 13–17 years
old). Enrollment was managed so that adolescents comprised approxi-
mately 25% of the study population.
Dosing began in the morning (approximately 07:00) after com-
pletion of the baseline visit. Patients initially received LDX 30 mg/
day, OROS-MPH 18 mg/day, or placebo. If an acceptable response
was not achieved, dose adjustments were made in a stepwise
manner at weekly intervals to higher doses. An acceptable response
was deﬁned as at least a 30% reduction in ADHD-RS-IV total score
from baseline and a Clinical Global Impressions-Improvement (CGI-I)
rating of 1 (very much improved) or 2 (much improved), with
tolerable adverse effects. A reduction of one dose level was
permitted if individuals experienced an intolerable adverse effect.
Doses could not be modiﬁed after visit 3; patients unable to
tolerate the study drug were withdrawn from the study. Participants
who achieved an acceptable response were maintained on their
optimal dose for the remainder of the double-blind evaluation
period (visits 4–7). Weekly on-site visits were scheduled for assess-
ments of safety and efﬁcacy, with reference to baseline.
2.3. Efﬁcacy
The primary efﬁcacy measure was the change from baseline in the
investigator-rated ADHD-RS-IV total score at endpoint. Endpoint
was deﬁned as the last on-therapy, post-randomization treatment
visit at which a valid ADHD-RS-IV total score was observed. The
ADHD-RS-IV consists of 18 items designed to reﬂect current
symptomatology of ADHD, based on DSM-IV-TR criteria. Each item
is scored on a 4-point scale, ranging from 0 (no symptoms) to 3
(severe symptoms), with the total score ranging from 0 to 54. The
scale is divided into two subscales (hyperactivity/impulsivity and
inattention) of nine items each. A decrease from baseline in ADHD-
RS-IV score indicated improvement in ADHD symptoms.
The key secondary efﬁcacy measure was the CGI-I rating. The
CGI-I is a 7-point global measure of clinical and functional improve-
ment ranging from 1 (very much improved) to 7 (very much worse).
At baseline, the CGI-Severity (CGI-S) rating was used to measure the
severity of each patient’s condition on a 7-point scale, ranging from
1 (normal, not at all ill) to 7 (among the most extremely ill). At
each subsequent visit, the investigator assessed the individual’s
improvement relative to baseline using the CGI-I rating; results
were categorized as ‘improved’ (all patients regarded as ‘very
much improved’ or ‘much improved’ [i.e. CGI-I of 1 or 2]) or ‘not
improved’ (all other scores).
2.4. Safety
Safety assessments included treatment-emergent adverse events
(TEAEs), clinical laboratory evaluations, physical examinations,
vital signs, and electrocardiograms. TEAEs were deﬁned as adverse
events that started or worsened during the period between the ﬁrst
dose of study drug and the third day (inclusive) following cessation
of treatment. TEAEs were coded using the current version of the
Medical Dictionary for Regulatory Activities (version 11.1) and
summarized by system organ class, preferred term, and treatment
group for the number and proportion reporting the event. TEAE
intensity was classiﬁed as mild (easily tolerated and does not
interfere with usual activity), moderate (interferes with usual
activity, but patient is still able to function), or severe (incapaci-
tating and patient is unable to work or complete usual activity).2.5. Statistical analyses
Safety outcomes were assessed for the safety population, deﬁned as all
patients who took at least one dose of study drug. Efﬁcacy outcomes
were assessed for the full analysis set, deﬁned as all patients who were
randomized and took at least one dose of study drug, but excluding
patients (n=15) from one site owing to violations of Good Clinical
Practice. A last observation carried forward approach (excluding base-
line) was used when efﬁcacy assessments were incomplete for a patient
owing to early withdrawal from the study or missing data.
The changes from baseline in the ADHD-RS-IV total and subscales
scores at each study visit and endpoint were analyzed using an analysis
of covariance (ANCOVA) model. Least squares (LS) mean and p values
were based on type III sum of squares from the ANCOVA model for the
change from baseline, including treatment group (effect of interest),
country and age group (randomization blocking factors), and the
corresponding baseline score (covariate). The primary treatment
comparison (LDX versus placebo) was evaluated at a signiﬁcance level
of 0.05 (two-sided). The null hypothesis stated that there was no
difference between LDX and placebo at endpoint, with the two-sided
alternative of a non-zero difference between groups. The Cochran–
Mantel–Haenszel test stratiﬁed by country and age group was used to
assess the key secondary efﬁcacy measure (CGI-I), and compared the
proportions of patients in each treatment group who were ‘improved’
and ‘not improved’ at each study visit and at endpoint. The statistical
analysis plan for the study did not prespecify a formal statistical
comparison between LDX and OROS-MPH.
Effect sizes based on the changes in ADHD-RS-IV total and subscale
scores were calculated as the difference (active drugplacebo) in LS
mean score, divided by the root mean square error obtained from the
ANCOVA model. Effect sizes of 0.2, 0.5, and 0.8 are traditionally held to
correspond to small, medium, and large magnitudes of effect, respec-
tively (Cohen, 1992). To detect an effect size of at least 0.45 for LDX
compared with placebo, with power of 90% and signiﬁcance level of
0.05 (two-sided) using a two-sample t-test with equal allocation to
treatment groups, 111 randomized patients were required for each
treatment group. A further 111 participants were randomized to an
OROS-MPH group to provide reference data for an approved comparator
product. Therefore, inclusion of a total of 333 randomized patients was
planned.
3. Results
3.1. Patient disposition and baseline
characteristics
The study was conducted between 17 November 2008 and 16
March 2011 at 48 centers in 10 European countries (Germany,
Sweden, Spain, Hungary, France, the UK, Italy, Belgium, Poland,
and the Netherlands). Of 336 randomized patients, 196 (58.3%)
completed the study (Figure 1). The most frequently reported
reason for study discontinuation was the lack of efﬁcacy, which
occurred in 11/113 (9.7%), 54/111 (48.6%), and 22/112 (19.6%)
patients treated with LDX, placebo, and OROS-MPH, respec-
tively (Figure 1). Baseline characteristics were similar across
treatment groups (Table 1). The mean age (7 standard
deviation [SD]) across treatment groups was 10.972.8 years;
children and adolescents comprised 71.1% and 28.9% of
patients, respectively (safety population).
3.2. Dose optimization
Following dose optimization, 20/111 (18.0%) patients in the
LDX treatment group received an optimal dose of 30 mg/day
Figure 1 Patient disposition. aSafety population included all patients who took one dose of any study drug. bFull analysis set
included all patients who were randomized and took at least one dose of study drug; patients from one site (n=15) were excluded
from the full analysis set owing to violations of Good Clinical Practice. cOne patient (placebo group) had a missing end-of-study
page, so the number of completers plus number of early terminators is one less than the number randomized. dOther reasons for
study discontinuation included: unable to swallow capsule, personal reasons due to family, and medical monitor decision.
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patients received 50 mg/day, and 37/111 (33.3%) patients
received 70 mg/day (safety population). In the OROS-MPH
treatment group, 11/111 (9.9%) patients were optimized to
18 mg/day, 22/111 (19.8%) patients to 36 mg/day, and 59/
111 (53.2%) patients to 54 mg/day (safety population). The
mean (7 SD) optimal dose was 53.8715.6 mg/day for LDX
and 45.4712.7 mg/day for OROS-MPH (safety population).3.3. Efﬁcacy
ADHD-RS-IV total scores at baseline were similar across
treatment groups (Table 1). Mean (7 SD) ADHD-RS-IV total
scores at baseline and endpoint for each treatment group
are shown in Figure 2. The LS mean (7 standard error [SE])
changes in ADHD-RS-IV total score from baseline to endpointwere greater for LDX (24.371.2) and OROS-MPH
(18.771.1) than for placebo (5.771.1) (Figure 2). The
difference in LS mean change (95% conﬁdence interval [CI])
in ADHD-RS-IV total score between LDX and placebo was
statistically signiﬁcant in favor of LDX at study endpoint
(18.6 [21.5 to 15.7], po0.001) and at every on-
treatment visit (po0.001 for all visits) (Figure 3). The
difference in LS mean change (95% CI) in ADHD-RS-IV total
score between OROS-MPH and placebo was statistically
signiﬁcant in favor of OROS-MPH at study endpoint (13.0
[15.9 to 10.2], po0.001) and at every on-treatment visit
(po0.01 at visit 1, po0.001 thereafter). Effect sizes based
on the difference (active drug  placebo) in LS mean
change in ADHD-RS-IV total score from baseline to endpoint
were 1.80 and 1.26 for LDX and OROS-MPH, respectively.
The decreases in both the ADHD-RS-IV hyperactivity/
impulsivity and inattention subscale scores from baseline
Figure 2 ADHD-RS-IV mean total scores at baseline and endpoint (7SD), and LS mean changes (7SE) from baseline to endpoint
(full analysis set). nnpo0.001 based on difference in LS mean change (active drugplacebo). Endpoint is the last on-treatment, post-
baseline visit of the dose-optimization or dose-maintenance period (visits 1–7) with a valid ADHD-RS-IV total score. A decrease from
baseline in the ADHD-RS-IV total score indicates an improvement in ADHD symptomatology.
Figure 3 LS mean changes (7SE) in ADHD-RS-IV mean total scores from baseline at each study visit (full analysis set). npo0.01,
nnpo0.001 based on difference in LS mean change (active drug – placebo). Endpoint is the last on-treatment, post-baseline visit of
the dose-optimization or dose-maintenance period (visits 1–7) with a valid ADHD-RS-IV total score. Visit 7 was the last day of
treatment and the interval between visits 7 and 8 was a 1-week post-treatment washout period. A decrease from baseline in the
ADHD-RS-IV total score indicates an improvement in ADHD symptomatology.
D. Coghill et al.1212to endpoint were also signiﬁcantly greater for both LDX and
OROS-MPH than for placebo (Figure 4). The differences in LS
mean change (95% CI) from baseline to endpoint between LDX
and placebo were statistically signiﬁcant for the hyperactivity/
impulsivity (8.7 [10.3 to 7.2], po0.001; effect size, 1.60)
and inattention (9.9 [11.5 to 8.3], po0.001; effect size,
1.72) subscale scores. The differences between OROS-MPH and
placebo in LS mean (95% CI) change from baseline to endpoint
were signiﬁcant for the hyperactivity/impulsivity (6.0 [7.5
to 4.5], po0.001; effect size, 1.11) and inattention (7.0
[8.6 to 5.4], po0.001; effect size, 1.22) subscale scores.
The proportions (95% CI) of patients with a CGI-I rating of
1 (‘very much improved’) or 2 (‘much improved’) at end-
point were 78% (70–86), 14% (8–21), and 61% (51–70) for LDX,
placebo, and OROS-MPH, respectively (Figure 5). The dif-
ference between LDX and placebo in the proportion ofindividuals categorized as ‘improved’ was statistically sig-
niﬁcant at visits 1–7 and at endpoint (po0.001, Figure 5).
The difference between OROS-MPH and placebo for the
proportion of patients with a CGI-I rating of 1 or 2 was
statistically signiﬁcant at visits 2–7 and at endpoint
(po0.001, Figure 5).3.4. Safety
TEAEs were experienced by 80/111 (72.1%), 63/110 (57.3%),
and 72/111 (64.9%) patients receiving LDX, placebo, and
OROS-MPH, respectively (Table 2). TEAEs with a frequency
of at least 5% in those receiving LDX included decreased
appetite, headache, insomnia, decreased weight, nausea,
and anorexia (Table 2). Most TEAEs were mild or moderate
1213Study of LDX in children and adolescents with ADHDin intensity (Table 2). The proportions of patients who
reported serious TEAEs were low across all treatment groups
(Table 2). The serious TEAEs were considered by the
investigators not to be related to the study drug, with one
exception in the OROS-MPH group (overdose). No deaths
were reported in this study and few patients experienced a
TEAE leading to discontinuation of study drug (Table 2).
TEAEs leading to discontinuation of study drug in the LDX
group were vomiting, anorexia, decreased appetite, angina
pectoris, tachycardia, decreased weight, and insomnia. The
case of angina pectoris was a 13-year old boy who experi-
enced pre-cardiac pain, which was considered by the studyFigure 4 LS mean change (7SE) from baseline to endpoint for
ADHD-RS-IV inattention and hyperactivity/impulsivity subscale
scores (full analysis set). po0.001 based on difference in LS
mean change (active drugplacebo). Endpoint is the last on-
treatment, post-baseline visit of the dose-optimization or dose-
maintenance period (visits 1–7) with a valid ADHD-RS-IV total
score. A decrease from baseline in the ADHD-RS-IV subscale
score indicates an improvement in ADHD symptomatology.
Figure 5 Proportion of patients with a CGI-I rating of 1 (‘very mu
visit compared with baseline (full analysis set). npo0.01, nnpo0
stratiﬁed by country and age group). Percentages are based on the
group. Endpoint is the last on-treatment, post-baseline visit of the d
valid CGI-I assessment. The interval between visits 7 and 8 was a 1investigator to be of moderate intensity and did not meet
the criteria for a serious TEAE. During the study, this patient
had no clinically signiﬁcant laboratory abnormalities, no
treatment or concomitant medications were reported and
all electrocardiograms were normal. Decreased appetite,
irritability, and insomnia were the TEAEs that led to
discontinuation of study drug in the OROS-MPH group.
LDX and OROS-MPH were associated with modest
increases in mean pulse rate, heart rate, systolic blood
pressure, and diastolic blood pressure, and decreases in
mean body weight from baseline to endpoint (Table 3). Of
47 patients (LDX, n=35; OROS-MPH, n=12) who had a
potentially clinically signiﬁcant decrease in weight at
endpoint (Z7% from baseline), three patients (LDX, n=2;
OROS-MPH, n=1) moved from healthy weight BMI cate-
gories to underweight (deﬁned as BMI less than the 5th
percentile).4. Discussion
In this European, 7-week, phase 3 study, LDX was more
effective than placebo in improving symptoms in children and
adolescents with ADHD. Compared with placebo, signiﬁcant
improvements in both ADHD core symptoms and global func-
tioning were observed. LDX was well tolerated, with TEAEs
consistent with those reported in previous studies. Robust
efﬁcacy outcomes were also observed for OROS-MPH, which
was included in this study as a reference arm.
The primary outcome measure was the change from base-
line in ADHD-RS-IV total score. Mean ADHD-RS-IV total scores
at baseline were indicative of moderate-to-marked symptoms
before administration of study drug (Goodman et al., 2010).
LDX produced a decrease in ADHD-RS-IV total score from
baseline that was signiﬁcantly greater than placebo by the
ﬁrst on-treatment study visit, scheduled 1 week following
treatment initiation. At endpoint, the mean ADHD-RS-IV total
score in patients treated with LDX was reduced by more than
50% compared with baseline. A 50% reduction in ADHD-RS-IVch improved’) or 2 (‘much improved’) (795% CI) at each study
.001 versus placebo (based on Cochran–Mantel–Haenszel test
number of patients with data at that visit in each treatment
ose-optimization or dose-maintenance period (visits 1–7) with a
-week post-treatment washout period.
Table 1 Baseline characteristics and demographic data according to treatment group (safety population).
Characteristic LDX (n=111) Placebo (n=110) OROS-MPH (n=111)
Age (years)
Mean (SD) 10.9 (2.9) 11.0 (2.8) 10.9 (2.6)
Median (range) 11.0 (6–17) 11.0 (6–17) 11.0 (6–16)
Age distribution (years), n (%)
6–12 77 (69.4) 79 (71.8) 80 (72.1)
13–17 34 (30.6) 31 (28.2) 31 (27.9)
Male, n (%) 87 (78.4) 91 (82.7) 90 (81.1)
Ethnicity, n (%)
Hispanic or Latino 2 (1.8) 0 2 (1.8)
Not Hispanic or Latino 109 (98.2) 110 (100.0) 109 (98.2)
Race, n (%)
White 107 (96.4) 108 (98.2) 107 (96.4)
Black or African American 1 (0.9) 0 0
Asian 1 (0.9) 0 0
Other 2 (1.8) 2 (1.8) 4 (3.6)
Body mass index (kg/m2)
Mean (SD) 19.3 (3.7) 19.0 (3.3) 19.1 (3.2)
Median (range) 18.6 (13.9–29.7) 18.0 (13.9–27.3) 18.6 (14.3–29.8)
ADHD-RS-IV total score at baselinea
Mean (SD) 41.0 (7.3) 41.2 (7.2) 40.4 (6.8)
Median (range) 41.0 (28–54) 42.0 (28–54) 40.0 (28–54)
ADHD-RS-IV hyperactivity/impulsivity subscale score at baselinea
Mean (SD) 18.5 (6.2) 19.3 (5.1) 18.5 (5.5)
Median (range) 20.0 (1–27) 20.0 (8–27) 19.0 (1–27)
ADHD-RS-IV inattention subscale score at baselinea
Mean (SD) 22.6 (3.4) 21.9 (3.7) 21.9 (3.5)
Median (range) 23.0 (13–27) 22.0 (10–27) 22.0 (14–27)
CGI-S rating at baselinea
Mean (SD) 5.0 (0.8) 4.9 (0.8) 5.0 (0.8)
Median (range) 5.0 (4–7) 5.0 (3–7) 5.0 (3–7)
ADHD subtypeb, n (%)
Predominantly inattentive 23 (20.7) 16 (14.5) 14 (12.7)
Predominantly hyperactive-impulsive 2 (1.8) 7 (6.4) 1 (0.9)
Combined 86 (77.5) 87 (79.1) 95 (86.4)
Time since ADHD diagnosis (years)b
Mean (SD) 2.4 (2.9) 2.2 (2.6) 2.2 (2.5)
Median (range) 1.3 (0.0–10.9) 0.90 (0.0–10.2) 0.8 (0.0–9.0)
Concomitant psychiatric diagnosis, n (%)c
Any 19 (17.1) 20 (18.2) 29 (26.1)
Oppositional deﬁant disorder 8 (7.2) 8 (7.3) 10 (9.0)
Previously treated with any ADHD medication, n (%) 64 (57.7) 58 (52.7) 60 (54.1)
aFive patients had no baseline ADHD-RS-IV total score, ADHD-RS-IV hyperactivity/impulsivity subscale score, ADHD-RS-IV inattention
subscale score and CGI-S rating.
bOne patient in the OROS-MPH group was not evaluated for ADHD subtype or time since ADHD diagnosis. Percentages are based on
the number of patients in each treatment group.
cPatients with at least one ongoing deﬁnite psychiatric diagnosis based on the Kiddie-Schedule for Affective Disorders and
Schizophrenia for school age children – Present and Lifetime – diagnostic interview.
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Table 2 Summary of TEAEs according to treatment group (safety population).
TEAE—preferred term, n (%) LDX (n=111) Placebo (n=110) OROS-MPH (n=111)
Any TEAE 80 (72.1) 63 (57.3) 72 (64.9)
Mild 33 (29.7) 35 (31.8) 30 (27.0)
Moderate 40 (36.0) 25 (22.7) 40 (36.0)
Severe 7 (6.3) 3 (2.7) 2 (1.8)
Any serious TEAEa 3 (2.7) 3 (2.7) 2 (1.8)
Any TEAE leading to discontinuation of study drug 5 (4.5) 4 (3.6) 2 (1.8)
TEAEs (Z5% of patients in any treatment group)b
Decreased appetite 28 (25.2) 3 (2.7) 17 (15.3)
Headache 16 (14.4) 22 (20.0) 22 (19.8)
Insomnia 16 (14.4) 0 9 (8.1)
Decreased weight 15 (13.5) 0 5 (4.5)
Nausea 12 (10.8) 3 (2.7) 8 (7.2)
Anorexia 12 (10.8) 2 (1.8) 6 (5.4)
Nasopharyngitis 8 (7.2) 8 (7.3) 14 (12.6)
Upper abdominal pain 8 (7.2) 6 (5.5) 9 (8.1)
Abdominal pain 6 (5.4) 6 (5.5) 4 (3.6)
Sleep disorder 6 (5.4) 1 (0.9) 2 (1.8)
Cough 3 (2.7) 0 8 (7.2)
Initial insomnia 3 (2.7) 1 (0.9) 7 (6.3)
aSerious TEAEs were syncope, gastroesophageal reﬂux disease, appendicitis (LDX); loss of consciousness, hematoma, clavicle
fracture (placebo); overdose, syncope (OROS-MPH).
bTEAEs are presented in order of decreasing frequency in the LDX treatment group.
Table 3 Summary of vital signs, weight, and electrocardiogram parameters (safety population).
LDX (n=111) Placebo (n=110) OROS-MPH (n=111)
Systolic blood pressure (mmHg)
Baseline, mean (SD) 107.4 (10.4) 107.8 (10.4) 107.1 (9.9)
Endpoint, mean change (SD) +1.0 (9.8) +1.0 (9.6) +0.3 (11.1)
Diastolic blood pressure (mmHg)
Baseline, mean (SD) 68.3 (9.9) 66.1 (9.1) 65.0 (9.5)
Endpoint, mean change (SD) +0.2 (9.6) +1.2 (8.7) +1.7 (9.9)
Pulse (bpm)
Baseline, mean (SD) 75.0 (11.7) 77.5 (11.5) 76.6 (10.2)
Endpoint, mean change (SD) +5.5 (13.2) 0.6 (10.6) +3.4 (13.2)
Weight (kg)
Baseline, mean (SD) 45.0 (17.5) 43.1 (14.0) 43.6 (15.1)
Endpoint, mean change (SD) 2.1 (1.9) +0.7 (1.0) 1.3 (1.4)
Heart rate (bpm)
Baseline, mean (SD) 74.6 (12.1) 77.2 (10.3) 75.9 (10.2)
Endpoint, mean change (SD) +5.7 (15.3) 1.1 (9.6) +5.0 (12.8)
QTcF interval (ms)
Baseline, mean (SD) 376.9 (16.4) 377.9 (17.4) 375.9 (16.4)
Endpoint, mean change (SD) +0.3 (15.6) +2.0 (13.6) +0.2 (15.9)
bpm, beats per minute; QTcF, QT interval corrected using Fridericia’s formula.
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meaningful than the 25% or 30% reduction thresholds that
are often used to deﬁne a response in clinical trials (Goodmanet al., 2010). Similar treatment beneﬁts were observed for
both the hyperactivity/impulsivity and inattention subscales
of the ADHD-RS-IV.
D. Coghill et al.1216The large effect size obtained for LDX (1.80) is similar to
those obtained previously in a ﬁxed-dose study conducted in
North America (range, 1.21–1.60) (Biederman et al., 2007b)
and indicates robust treatment efﬁcacy (Cohen, 1992).
Although several factors can inﬂuence effect sizes
(Faraone, 2012), preliminary investigations have suggested
that the small SD values obtained for the change in ADHD-
RS-IV score in the LDX and placebo groups do not account for
the large magnitude of the effect size. It is, however,
possible that the smaller than usual placebo response did,
at least in part, contribute to this large treatment effect.
ADHD is currently less frequently diagnosed in Europe than
in North America, with evidence of under-recognition and
under-diagnosis (NHS Quality Improvement Scotland, 2008).
Consequently, it is likely that those individuals who are
diagnosed are at the more severe end of the spectrum and
would therefore be less likely to show a response to
placebo. In agreement with this suggestion, reassessment
of data from the Multimodal Treatment of ADHD (MTA) study
demonstrated that children who had been diagnosed with
ADHD based on DSM-IV criteria, but also met the more
restrictive International Classiﬁcation of Diseases-10 criteria
for hyperkinetic disorder, showed a more robust response to
medication compared with those who met DSM-IV criteria
alone (Santosh et al., 2005).
In addition to reducing the core symptoms of ADHD, this
trial has also demonstrated that LDX improved global
functioning, as assessed using the CGI-I rating. The propor-
tion of patients with an improved CGI-I rating was higher in
the LDX group than in the placebo group at every on-
treatment study visit, with 78% of participants reportedly
‘very much improved’ or ‘much improved’ (CGI-I score of
1 or 2) at study endpoint compared with 14% of patients in
the placebo group.
This study was not designed to provide a head-to-head
comparison between LDX and OROS-MPH. However, the
results observed for the OROS-MPH reference arm support
the validity and sensitivity of the study design and execu-
tion. OROS-MPH treatment produced a signiﬁcantly greater
improvement in ADHD-RS-IV total score than placebo, with a
large effect size of 1.26. Furthermore, a signiﬁcantly
greater proportion of patients taking OROS-MPH had a
CGI-I rating of 1 or 2 from the second on-treatment study
visit (visit 2) compared with those who received placebo.
LDX and OROS-MPH were generally well tolerated in this
study, and most TEAEs were mild or moderate in severity.
The safety proﬁle of LDX was consistent with that reported
in previous studies (Adler et al., 2008; Biederman et al.,
2007a, 2007b; Findling et al., 2011) and with the known
effects of stimulant medications (May and Kratochvil, 2010).
Anorexia, decreased appetite, decreased weight, insomnia,
and nausea were more common in patients treated with LDX
than in those who received OROS-MPH, whereas headache was
reported more frequently in the OROS-MPH treatment group
than in the LDX treatment group. Most participants receiving
LDX and OROS-MPH completed the study. In the LDX treatment
group, TEAEs that led to discontinuation of study drug
included anorexia, decreased appetite and vomiting. In the
OROS-MPH group, one participant discontinued owing to
decreased appetite; none discontinued due to vomiting.
The modest mean increases from baseline in heart rate
and pulse rate in patients receiving LDX and OROS-MPH areconsistent with the known safety proﬁles of stimulant
medications (May and Kratochvil, 2010). The decrease in
mean weight that was observed in the LDX treatment group
was greater than that observed in the OROS-MPH group.
However, at endpoint, most patients remained within their
baseline BMI category and few participants had weight
changes that resulted in a shift to the underweight BMI
category. The clinical signiﬁcance of the observed weight
loss in patients treated with LDX is unclear, given the short-
term nature of the trial. An open-label investigation into
the long-term (up to 12 months) efﬁcacy and safety of LDX
in school-aged children found that weight increased in
patients taking LDX over the course of the study (Findling
et al., 2008). However, the rate of this increase was below
the age- and sex-norm, suggesting that weight should be
monitored during extended LDX treatment. The long-term
efﬁcacy and safety of LDX is being investigated in an
extension to the present study, which includes an open
label phase followed by a randomized, double-blind,
withdrawal phase.
The strengths of this study include its randomized,
double-blind, placebo-controlled design, the large number
of patients enrolled at multiple centers across Europe, and
the inclusion both of children and of adolescents. However,
there are some limitations that should be taken into
consideration when interpreting the results. Firstly, indivi-
duals with comorbid conditions, such as post-traumatic
stress disorder, bipolar affective disorder, or severe anxiety
disorder, were excluded from this study. Secondly, due to
European regulations, the maximum dose of OROS-MPH that
was administered in this study was 54 mg/day. In the US,
72 mg/day OROS-MPH has been approved for the treatment
of patients with ADHD who are at least 13 years old
(American Academy of Pediatrics, 2011a). Nevertheless, a
robust effect size (1.26) based on the change in ADHD-RS-IV
total score from baseline to endpoint was obtained for
patients treated with OROS-MPH. Finally, compared with a
ﬁxed-dose methodology, the 3-week dose-optimization per-
iod was designed to reﬂect more closely the common
prescribing practices of clinicians treating patients with
ADHD. The optimized-dose design of the study did, however,
preclude evaluation of the dose-dependency of either
efﬁcacy or safety outcomes, as well as conﬁrmation of dose
equivalence between LDX and OROS-MPH.
This phase 3 study was the ﬁrst in Europe to evaluate the
efﬁcacy and safety of a once-daily optimized dose of LDX in
children and adolescents with at least moderately symptomatic
ADHD. LDX was more effective than placebo in improving core
symptoms and global functioning in patients with ADHD, and
demonstrated a safety proﬁle consistent with the results from
previous studies and with long-acting stimulant use.
Role of the funding source
This study was supported by funding from Shire Develop-
ment LLC.
Contributors
T Banaschewski, D Coghill, M Johnson, M Lecendreux, C Soutullo,
and A Zuddas were principal investigators in this clinical study.
1217Study of LDX in children and adolescents with ADHDC Anderson, R Civil, N Higgins, A Lyne, and L Squires contributed to
the study design. A Lyne was responsible for the statistical analysis.
All authors were involved in discussion and interpretation of the
data and have critically revised the article and approved the
manuscript before submission.
Conﬂict of interest
C Anderson, R Civil, N Higgins, A Lyne, and L Squires are employees
of Shire and own stock/stock options. The following authors have
received compensation for serving as consultants or speakers, or
they or the institutions they work for have received research
support or royalties from the companies or organizations indicated:
D Coghill (Flynn, Janssen Cilag, Lilly, Medice, Novartis, Otsuka,
Oxford University Press, Pﬁzer, Schering-Plough, Shire, UCB, Vifor
Pharma); T Banaschewski (Bristol-Myers Squibb, Desitin, Develco
Pharma, Janssen McNeil, Lilly, Medice, Novartis, Shire, UCB, Vifor
Pharma); M Lecendreux (Shire, UCB, Vifor Pharma); C Soutullo
(Abbott, Alicia Koplowitz Foundation, AstraZeneca, Bristol-Myers
Squibb, Carlos III Institute [FIS]: Redes Tematicas de Investigacio´n
Cooperativa, DOYMA, Editorial M edica Panamericana, Eli Lilly,
EUNSA, European Interdisciplinary Network ADHD Quality Assur-
ance, Euro RSCG Life Medea, GlaxoSmithKline, Gobierno de
Navarra, Grupo Aula M edica, Grupo Correo, Janssen, Medice/Juste,
Novartis, Otsuka, Pﬁzer, University of Navarra Research Projects
(PIUNA), SEP-SEPB, Shire, Sociedad Vasco-Navarra Psiquiatr´ıa, Sol-
vay, Stanley Medical Research Institute-National Alliance on Mental
Illness, Wolters Kluwer); M Johnson (Janssen, Lilly, Novartis, Shire,
Vifor Pharma, WM Lundgrens Research Fund); A Zuddas
(AstraZeneca, Bristol-Myers Squibb/Otsuka, Lilly, Lundbeck, Shire,
Vifor Pharma).
Acknowledgments
The authors thank the patients and the investigators who took part
in this study, and Dr. Eric Southam and Dr. Elizabeth Gandhi of
Oxford PharmaGenesisTM Ltd. for editorial assistance, collating the
comments of the authors, and editing the manuscript for
submission.
References
American Psychiatric Association, 2000. Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-
IV-TR). American Psychiatric Association, Washington DC.
Adler, L.A., Goodman, D.W., Kollins, S.H., Weisler, R.H., Krishnan,
S., Zhang, Y., Biederman, J., 2008. Double-blind, placebo-
controlled study of the efﬁcacy and safety of lisdexamfetamine
dimesylate in adults with attention-deﬁcit/hyperactivity disor-
der. J. Clin. Psychiatry 69, 1364–1373.
American Academy of Pediatrics, 2011a. ADHD: clinical practice
guideline for the diagnosis, evaluation, and treatment of atten-
tion-deﬁcit/hyperactivity disorder in children and adolescents.
Process of care supplemental appendix. Pediatrics 128, SI1–SI21
/http://pediatrics.aappublications.org/content/suppl/2011/10/11/
peds.2011-2654.DC1/zpe611117822p.pdfS (accessed 22.05.12).
American Academy of Pediatrics, 2011b. ADHD: clinical practice
guideline for the diagnosis, evaluation, and treatment of atten-
tion-deﬁcit/hyperactivity disorder in children and adolescents.
Pediatrics 128, 1007–1022.
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P.,
Buitelaar, J., Danckaerts, M., Dopfner, M., Faraone, S.V.,
Rothenberger, A., Sergeant, J., Steinhausen, H.C., Sonuga-
Barke, E.J., Taylor, E., 2006. Long-acting medications for the
hyperkinetic disorders. A systematic review and European
treatment guideline. Eur. Child Adolesc. Psychiatry 15, 476–495.Biederman, J., Boellner, S.W., Childress, A., Lopez, F.A., Krishnan,
S., Zhang, Y., 2007a. Lisdexamfetamine dimesylate and mixed
amphetamine salts extended-release in children with ADHD: a
double-blind, placebo-controlled, crossover analog classroom
study. Biol. Psychiatry 62, 970–976.
Biederman, J., Krishnan, S., Zhang, Y., McGough, J.J., Findling,
R.L., 2007b. Efﬁcacy and tolerability of lisdexamfetamine
dimesylate (NRP-104) in children with attention-deﬁcit/hyper-
activity disorder: a phase III, multicenter, randomized, double-
blind, forced-dose, parallel-group study. Clin. Ther. 29, 450–463.
Boellner, S.W., Stark, J.G., Krishnan, S., Zhang, Y., 2010. Pharma-
cokinetics of lisdexamfetamine dimesylate and its active meta-
bolite, d-amphetamine, with increasing oral doses of
lisdexamfetamine dimesylate in children with attention-deﬁ-
cit/hyperactivity disorder: a single-dose, randomized, open-
label, crossover study. Clin. Ther. 32, 252–264.
Cohen, J., 1992. A power primer. Psychol. Bull. 112, 155–159.
Faraone, S.V., 2012. Understanding the effect size of lisdexamfe-
tamine dimesylate for treating ADHD in children and adults. J.
Atten. Disord. 16, 128–137.
Findling, R.L., Childress, A.C., Cutler, A.J., Gasior, M., Hamdani,
M., Ferreira-Cornwell, M.C., Squires, L., 2011. Efﬁcacy and
safety of lisdexamfetamine dimesylate in adolescents with
attention-deﬁcit/hyperactivity disorder. J. Am. Acad. Child
Adolesc. Psychiatry 50, 395–405.
Findling, R.L., Childress, A.C., Krishnan, S., McGough, J.J., 2008.
Long-term effectiveness and safety of lisdexamfetamine dime-
sylate in school-aged children with attention-deﬁcit/hyperac-
tivity disorder. CNS Spectrums 13, 614–620.
Goodman, D., Faraone, S.V., Adler, L.A., Dirks, B., Hamdani, M.,
Weisler, R., 2010. Interpreting ADHD rating scale scores: linking
ADHD rating scale scores and CGI levels in randomized controlled
trials of lisdexamfetamine dimesylate in ADHD. Primary Psychia-
try 17, 44–52.
Gordon, M., Antshel, K., Faraone, S., Barkley, R., Lewandowski, L.,
Hudziak, J.J., Biederman, J., Cunningham, C., 2006. Symptoms
versus impairment: the case for respecting DSM-IV’s Criterion D.
J. Atten. Disord. 9, 465–475.
May, D.E., Kratochvil, C.J., 2010. Attention-deﬁcit hyperactivity
disorder: recent advances in paediatric pharmacotherapy. Drugs
70, 15–40.
National Institute for Health and Clinical Excellence, 2009. Diag-
nosis and Management of ADHD in Children, Young People and
Adults. National Clinical Practice Guideline Number 72. London,
UK. /http://www.nice.org.uk/nicemedia/live/12061/42060/
42060.pdfS (accessed 26.04.2012).
NHS Quality Improvement Scotland, 2008. Attention Deﬁcit and
Hyperkinetic Disorders. Services Over Scotland. Report of the
Implementation Review Exercise. Edinburgh, UK, p. 11876.
/http://www.healthcareimprovementscotland.org/default.aspx?S
(accessed 16.05.2012).
Pennick, M., 2010. Absorption of lisdexamfetamine dimesylate and
its enzymatic conversion to d-amphetamine. Neuropsychiatr.
Dis. Treat. 6, 317–327.
Polanczyk, G., de Lima, M.S., Horta, B.L., Biederman, J., Rohde,
L.A., 2007. The worldwide prevalence of ADHD: a systematic
review and metaregression analysis. Am. J. Psychiatry 164,
942–948.
Santosh, P.J., Taylor, E., Swanson, J., Wigal, T., Chuang, S., Davies,
M., Greenhill, L., Newcorn, J., Arnold, L.E., Jensen, P., Vitiello,
B., Elliott, G., Hinshaw, S.P., Hechtman, L., Abikoff, H., Pelham,
W.E., Wells, K., Posner, M., 2005. Reﬁning the diagnoses of
inattention and overactivity syndromes: a reanalysis of the
multimodal treatment study of attention deﬁcit hyperactivity
disorder (ADHD) based on ICD-10 criteria for hyperkinetic
disorder. Clin. Neurosci. Res. 5, 307–314.
Taylor, E., Dopfner, M., Sergeant, J., Asherson, P., Banaschewski, T.,
Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A.,
D. Coghill et al.1218Sonuga-Barke, J., Steinhausen, H.C., Zuddas, A., 2004. European
clinical guidelines for hyperkinetic disorder—ﬁrst upgrade. Eur.
Child Adolesc. Psychiatry 13 (Suppl. 1), I7–30.
Wigal, S.B., Kollins, S.H., Childress, A.C., Squires, L., 2009. A 13-
hour laboratory school study of lisdexamfetamine dimesylate in
school-aged children with attention-deﬁcit/hyperactivity disor-
der. Child Adolesc. Psychiatry Ment. Health 3, 17.Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., 2010.
Randomized, double-blind, placebo-controlled, crossover study of
the efﬁcacy and safety of lisdexamfetamine dimesylate in adults
with attention-deﬁcit/hyperactivity disorder: novel ﬁndings using a
simulated adult workplace environment design. Behav. Brain Funct.
6, 34.
